Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Gilead Sciences Inc., solvency ratios (quarterly data)
Based on: 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Gilead Sciences Inc.’s debt to equity ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Gilead Sciences Inc.’s debt to capital ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Gilead Sciences Inc.’s debt to assets ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Gilead Sciences Inc.’s financial leverage ratio increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Gilead Sciences Inc.’s interest coverage ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Debt to Equity
Gilead Sciences Inc., debt to equity calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Current portion of long-term debt | 1,498 | 2,999 | 1,999 | 2,499 | 2,498 | 1,999 | 2,498 | 2,748 | 2,747 | 2,998 | 2,497 | 2,747 | 1,747 | — | — | — | 700 | 700 | 1,745 | 983 | 331 | 352 | 442 | |||||||
Long-term debt, net, excluding current portion | 27,792 | 21,103 | 22,098 | 22,094 | 22,090 | 24,084 | 24,080 | 24,574 | 24,570 | 26,062 | 26,557 | 30,795 | 27,515 | 26,296 | 26,321 | 26,346 | 26,371 | 21,427 | 21,077 | 21,195 | 21,894 | 11,922 | 11,921 | |||||||
Total debt | 29,290 | 24,102 | 24,097 | 24,593 | 24,588 | 26,083 | 26,578 | 27,322 | 27,317 | 29,060 | 29,054 | 33,542 | 29,262 | 26,296 | 26,321 | 26,346 | 27,071 | 22,127 | 22,822 | 22,178 | 22,225 | 12,274 | 12,363 | |||||||
Total Gilead stockholders’ equity | 17,445 | 18,027 | 22,067 | 22,525 | 20,604 | 22,616 | 21,951 | 21,387 | 22,861 | 21,672 | 20,591 | 20,442 | 24,845 | 22,677 | 20,441 | 18,887 | 16,868 | 15,536 | 13,398 | 18,534 | 17,414 | 16,287 | 17,180 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to equity1 | 1.68 | 1.34 | 1.09 | 1.09 | 1.19 | 1.15 | 1.21 | 1.28 | 1.19 | 1.34 | 1.41 | 1.64 | 1.18 | 1.16 | 1.29 | 1.39 | 1.60 | 1.42 | 1.70 | 1.20 | 1.28 | 0.75 | 0.72 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 0.59 | 0.64 | 0.60 | 0.58 | 0.60 | 0.61 | 0.62 | 0.64 | 0.77 | 0.68 | 0.70 | 0.90 | 0.75 | 0.76 | 0.76 | 1.07 | 0.41 | 0.43 | 0.41 | 0.42 | 0.40 | 0.38 | 0.41 | |||||||
AbbVie Inc. | 5.70 | 5.94 | — | — | — | — | — | — | — | — | 10.49 | 7.33 | 5.65 | 6.20 | 7.39 | 7.95 | 5.77 | 6.71 | 6.87 | 8.03 | 6.61 | 5.65 | 11.09 | |||||||
Amgen Inc. | 3.13 | 3.21 | 3.36 | 3.09 | 2.73 | 2.84 | 3.05 | 2.71 | 2.40 | 2.31 | 2.28 | 1.40 | 1.11 | 1.11 | 1.11 | 1.16 | 1.15 | 1.10 | 1.20 | 1.12 | 1.14 | 1.16 | 1.14 | |||||||
Bristol-Myers Squibb Co. | 0.90 | 0.95 | 0.94 | 0.91 | 1.41 | 1.56 | 0.40 | 0.52 | 0.54 | 0.60 | 0.60 | 0.68 | 0.57 | 0.56 | 0.59 | 0.41 | 0.44 | 0.45 | 0.47 | 0.47 | 0.48 | 0.49 | 0.48 | |||||||
Eli Lilly & Co. | 3.51 | 3.99 | 5.60 | 5.88 | 4.50 | 5.68 | 6.44 | 1.30 | 0.97 | 1.06 | 0.81 | 1.18 | 0.90 | 0.87 | 0.73 | 0.74 | 0.60 | 0.64 | 0.54 | 0.55 | 0.53 | 0.55 | 0.55 | |||||||
Illumina Inc. | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.26 | 0.44 | 0.53 | 0.57 | 0.42 | 0.45 | 0.49 | 0.46 | 0.48 | 0.49 | 0.58 | 0.54 | 0.50 | 0.51 | 0.59 | 0.57 | 0.73 | 0.80 | |||||||
Johnson & Johnson | 0.59 | 0.48 | 0.45 | 0.47 | 0.50 | 0.48 | 0.50 | 0.51 | 0.48 | 0.51 | 0.51 | 0.57 | 0.48 | 0.48 | 0.46 | 0.39 | 0.37 | 0.36 | 0.32 | 0.28 | 0.28 | 0.27 | 0.28 | |||||||
Merck & Co. Inc. | 0.98 | 1.12 | 1.07 | 1.02 | 0.97 | 0.96 | 0.94 | 0.94 | 0.73 | 0.72 | 0.70 | 0.71 | 0.71 | 0.63 | 0.71 | 0.62 | 0.57 | 0.56 | 0.59 | 0.59 | 0.58 | 0.57 | 0.63 | |||||||
Pfizer Inc. | 0.97 | 0.99 | 0.80 | 0.83 | 0.81 | 0.78 | 0.77 | 0.66 | 0.58 | 0.58 | 0.56 | 0.61 | 0.72 | 0.75 | 0.75 | 0.71 | 0.70 | 0.70 | 0.62 | 0.60 | 0.58 | 0.53 | 0.53 | |||||||
Regeneron Pharmaceuticals Inc. | 0.27 | 0.24 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | 0.11 | 0.12 | 0.13 | 0.15 | 0.11 | 0.09 | 0.09 | 0.10 | 0.10 | 0.12 | 0.12 | 0.16 | |||||||
Vertex Pharmaceuticals Inc. | 0.07 | 0.07 | 0.08 | 0.09 | 0.10 | 0.11 | 0.12 | 0.13 | 0.20 | 0.22 | 0.24 | 0.29 | 0.32 | 0.33 | 0.35 | 0.71 | 0.79 | 0.82 | 0.84 | 0.86 | 0.87 | 0.91 | 0.83 | |||||||
Zoetis Inc. | 2.14 | 2.58 | 2.35 | 2.38 | 2.41 | 2.67 | 2.78 | 2.95 | 3.04 | 2.52 | 2.53 | 2.80 | 2.87 | 2.66 | 2.78 | 3.00 | 2.82 | 3.29 | 3.84 | 4.56 | 2.96 | 3.10 | 2.85 |
Based on: 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q3 2020 Calculation
Debt to equity = Total debt ÷ Total Gilead stockholders’ equity
= 29,290 ÷ 17,445 = 1.68
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Gilead Sciences Inc.’s debt to equity ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to Capital
Gilead Sciences Inc., debt to capital calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Current portion of long-term debt | 1,498 | 2,999 | 1,999 | 2,499 | 2,498 | 1,999 | 2,498 | 2,748 | 2,747 | 2,998 | 2,497 | 2,747 | 1,747 | — | — | — | 700 | 700 | 1,745 | 983 | 331 | 352 | 442 | |||||||
Long-term debt, net, excluding current portion | 27,792 | 21,103 | 22,098 | 22,094 | 22,090 | 24,084 | 24,080 | 24,574 | 24,570 | 26,062 | 26,557 | 30,795 | 27,515 | 26,296 | 26,321 | 26,346 | 26,371 | 21,427 | 21,077 | 21,195 | 21,894 | 11,922 | 11,921 | |||||||
Total debt | 29,290 | 24,102 | 24,097 | 24,593 | 24,588 | 26,083 | 26,578 | 27,322 | 27,317 | 29,060 | 29,054 | 33,542 | 29,262 | 26,296 | 26,321 | 26,346 | 27,071 | 22,127 | 22,822 | 22,178 | 22,225 | 12,274 | 12,363 | |||||||
Total Gilead stockholders’ equity | 17,445 | 18,027 | 22,067 | 22,525 | 20,604 | 22,616 | 21,951 | 21,387 | 22,861 | 21,672 | 20,591 | 20,442 | 24,845 | 22,677 | 20,441 | 18,887 | 16,868 | 15,536 | 13,398 | 18,534 | 17,414 | 16,287 | 17,180 | |||||||
Total capital | 46,735 | 42,129 | 46,164 | 47,118 | 45,192 | 48,699 | 48,529 | 48,709 | 50,178 | 50,732 | 49,645 | 53,984 | 54,107 | 48,973 | 46,762 | 45,233 | 43,939 | 37,663 | 36,220 | 40,712 | 39,639 | 28,561 | 29,543 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to capital1 | 0.63 | 0.57 | 0.52 | 0.52 | 0.54 | 0.54 | 0.55 | 0.56 | 0.54 | 0.57 | 0.59 | 0.62 | 0.54 | 0.54 | 0.56 | 0.58 | 0.62 | 0.59 | 0.63 | 0.54 | 0.56 | 0.43 | 0.42 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 0.37 | 0.39 | 0.38 | 0.37 | 0.38 | 0.38 | 0.38 | 0.39 | 0.43 | 0.40 | 0.41 | 0.47 | 0.43 | 0.43 | 0.43 | 0.52 | 0.29 | 0.30 | 0.29 | 0.30 | 0.28 | 0.28 | 0.29 | |||||||
AbbVie Inc. | 0.85 | 0.86 | 1.12 | 1.14 | 1.27 | 1.30 | 1.27 | 1.27 | 1.08 | 1.10 | 0.91 | 0.88 | 0.85 | 0.86 | 0.88 | 0.89 | 0.85 | 0.87 | 0.87 | 0.89 | 0.87 | 0.85 | 0.92 | |||||||
Amgen Inc. | 0.76 | 0.76 | 0.77 | 0.76 | 0.73 | 0.74 | 0.75 | 0.73 | 0.71 | 0.70 | 0.69 | 0.58 | 0.53 | 0.53 | 0.53 | 0.54 | 0.53 | 0.52 | 0.54 | 0.53 | 0.53 | 0.54 | 0.53 | |||||||
Bristol-Myers Squibb Co. | 0.47 | 0.49 | 0.48 | 0.48 | 0.59 | 0.61 | 0.28 | 0.34 | 0.35 | 0.37 | 0.38 | 0.40 | 0.36 | 0.36 | 0.37 | 0.29 | 0.30 | 0.31 | 0.32 | 0.32 | 0.33 | 0.33 | 0.32 | |||||||
Eli Lilly & Co. | 0.78 | 0.80 | 0.85 | 0.85 | 0.82 | 0.85 | 0.87 | 0.57 | 0.49 | 0.51 | 0.45 | 0.54 | 0.47 | 0.47 | 0.42 | 0.42 | 0.37 | 0.39 | 0.35 | 0.35 | 0.35 | 0.35 | 0.36 | |||||||
Illumina Inc. | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.21 | 0.30 | 0.35 | 0.36 | 0.30 | 0.31 | 0.33 | 0.31 | 0.32 | 0.33 | 0.37 | 0.35 | 0.33 | 0.34 | 0.37 | 0.36 | 0.42 | 0.44 | |||||||
Johnson & Johnson | 0.37 | 0.33 | 0.31 | 0.32 | 0.33 | 0.33 | 0.33 | 0.34 | 0.33 | 0.34 | 0.34 | 0.37 | 0.32 | 0.32 | 0.32 | 0.28 | 0.27 | 0.27 | 0.24 | 0.22 | 0.22 | 0.21 | 0.22 | |||||||
Merck & Co. Inc. | 0.50 | 0.53 | 0.52 | 0.50 | 0.49 | 0.49 | 0.48 | 0.48 | 0.42 | 0.42 | 0.41 | 0.42 | 0.41 | 0.39 | 0.42 | 0.38 | 0.36 | 0.36 | 0.37 | 0.37 | 0.37 | 0.36 | 0.39 | |||||||
Pfizer Inc. | 0.49 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.43 | 0.40 | 0.37 | 0.37 | 0.36 | 0.38 | 0.42 | 0.43 | 0.43 | 0.41 | 0.41 | 0.41 | 0.38 | 0.38 | 0.37 | 0.34 | 0.35 | |||||||
Regeneron Pharmaceuticals Inc. | 0.21 | 0.20 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.08 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.13 | 0.10 | 0.08 | 0.08 | 0.09 | 0.09 | 0.11 | 0.10 | 0.14 | |||||||
Vertex Pharmaceuticals Inc. | 0.06 | 0.06 | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | 0.12 | 0.17 | 0.18 | 0.19 | 0.22 | 0.24 | 0.25 | 0.26 | 0.42 | 0.44 | 0.45 | 0.46 | 0.46 | 0.47 | 0.48 | 0.45 | |||||||
Zoetis Inc. | 0.68 | 0.72 | 0.70 | 0.70 | 0.71 | 0.73 | 0.74 | 0.75 | 0.75 | 0.72 | 0.72 | 0.74 | 0.74 | 0.73 | 0.74 | 0.75 | 0.74 | 0.77 | 0.79 | 0.82 | 0.75 | 0.76 | 0.74 |
Based on: 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q3 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= 29,290 ÷ 46,735 = 0.63
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Gilead Sciences Inc.’s debt to capital ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to Assets
Gilead Sciences Inc., debt to assets calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Current portion of long-term debt | 1,498 | 2,999 | 1,999 | 2,499 | 2,498 | 1,999 | 2,498 | 2,748 | 2,747 | 2,998 | 2,497 | 2,747 | 1,747 | — | — | — | 700 | 700 | 1,745 | 983 | 331 | 352 | 442 | |||||||
Long-term debt, net, excluding current portion | 27,792 | 21,103 | 22,098 | 22,094 | 22,090 | 24,084 | 24,080 | 24,574 | 24,570 | 26,062 | 26,557 | 30,795 | 27,515 | 26,296 | 26,321 | 26,346 | 26,371 | 21,427 | 21,077 | 21,195 | 21,894 | 11,922 | 11,921 | |||||||
Total debt | 29,290 | 24,102 | 24,097 | 24,593 | 24,588 | 26,083 | 26,578 | 27,322 | 27,317 | 29,060 | 29,054 | 33,542 | 29,262 | 26,296 | 26,321 | 26,346 | 27,071 | 22,127 | 22,822 | 22,178 | 22,225 | 12,274 | 12,363 | |||||||
Total assets | 60,878 | 55,934 | 59,741 | 61,627 | 59,146 | 63,210 | 62,837 | 63,675 | 64,305 | 65,355 | 65,381 | 70,283 | 64,662 | 60,263 | 57,701 | 56,977 | 56,609 | 49,980 | 47,765 | 51,839 | 50,637 | 39,167 | 38,321 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to assets1 | 0.48 | 0.43 | 0.40 | 0.40 | 0.42 | 0.41 | 0.42 | 0.43 | 0.42 | 0.44 | 0.44 | 0.48 | 0.45 | 0.44 | 0.46 | 0.46 | 0.48 | 0.44 | 0.48 | 0.43 | 0.44 | 0.31 | 0.32 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 0.27 | 0.29 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | 0.29 | 0.33 | 0.30 | 0.31 | 0.37 | 0.33 | 0.34 | 0.34 | 0.42 | 0.22 | 0.22 | 0.22 | 0.22 | 0.20 | 0.20 | 0.21 | |||||||
AbbVie Inc. | 0.58 | 0.58 | 0.74 | 0.75 | 0.65 | 0.65 | 0.65 | 0.68 | 0.61 | 0.60 | 0.54 | 0.53 | 0.55 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.59 | 0.60 | 0.59 | 0.58 | 0.57 | |||||||
Amgen Inc. | 0.53 | 0.53 | 0.52 | 0.50 | 0.50 | 0.52 | 0.52 | 0.51 | 0.51 | 0.51 | 0.50 | 0.44 | 0.45 | 0.44 | 0.44 | 0.45 | 0.45 | 0.44 | 0.46 | 0.44 | 0.44 | 0.45 | 0.44 | |||||||
Bristol-Myers Squibb Co. | 0.36 | 0.36 | 0.36 | 0.36 | 0.43 | 0.45 | 0.17 | 0.21 | 0.22 | 0.23 | 0.23 | 0.24 | 0.25 | 0.25 | 0.26 | 0.20 | 0.20 | 0.21 | 0.21 | 0.21 | 0.23 | 0.23 | 0.22 | |||||||
Eli Lilly & Co. | 0.39 | 0.39 | 0.42 | 0.39 | 0.40 | 0.41 | 0.42 | 0.29 | 0.28 | 0.29 | 0.26 | 0.30 | 0.31 | 0.30 | 0.27 | 0.27 | 0.25 | 0.26 | 0.23 | 0.22 | 0.22 | 0.22 | 0.23 | |||||||
Illumina Inc. | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.24 | 0.29 | 0.29 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.27 | 0.30 | 0.29 | 0.26 | 0.27 | 0.30 | 0.30 | 0.35 | 0.37 | |||||||
Johnson & Johnson | 0.22 | 0.19 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | 0.20 | 0.20 | 0.21 | 0.21 | 0.22 | 0.23 | 0.23 | 0.22 | 0.19 | 0.19 | 0.19 | 0.17 | 0.15 | 0.15 | 0.15 | 0.15 | |||||||
Merck & Co. Inc. | 0.32 | 0.34 | 0.33 | 0.31 | 0.31 | 0.32 | 0.31 | 0.30 | 0.28 | 0.27 | 0.27 | 0.28 | 0.29 | 0.27 | 0.29 | 0.26 | 0.26 | 0.25 | 0.26 | 0.26 | 0.26 | 0.26 | 0.28 | |||||||
Pfizer Inc. | 0.35 | 0.36 | 0.31 | 0.31 | 0.31 | 0.30 | 0.29 | 0.26 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.26 | 0.24 | 0.23 | 0.23 | 0.22 | 0.22 | |||||||
Regeneron Pharmaceuticals Inc. | 0.17 | 0.15 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | 0.08 | 0.09 | 0.11 | |||||||
Vertex Pharmaceuticals Inc. | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.08 | 0.09 | 0.09 | 0.12 | 0.13 | 0.15 | 0.16 | 0.18 | 0.17 | 0.18 | 0.28 | 0.31 | 0.32 | 0.32 | 0.32 | 0.33 | 0.34 | 0.38 | |||||||
Zoetis Inc. | 0.56 | 0.59 | 0.56 | 0.56 | 0.57 | 0.59 | 0.59 | 0.60 | 0.62 | 0.58 | 0.57 | 0.58 | 0.61 | 0.59 | 0.58 | 0.58 | 0.58 | 0.59 | 0.60 | 0.62 | 0.54 | 0.55 | 0.57 |
Based on: 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q3 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= 29,290 ÷ 60,878 = 0.48
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Gilead Sciences Inc.’s debt to assets ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Financial Leverage
Gilead Sciences Inc., financial leverage calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Total assets | 60,878 | 55,934 | 59,741 | 61,627 | 59,146 | 63,210 | 62,837 | 63,675 | 64,305 | 65,355 | 65,381 | 70,283 | 64,662 | 60,263 | 57,701 | 56,977 | 56,609 | 49,980 | 47,765 | 51,839 | 50,637 | 39,167 | 38,321 | |||||||
Total Gilead stockholders’ equity | 17,445 | 18,027 | 22,067 | 22,525 | 20,604 | 22,616 | 21,951 | 21,387 | 22,861 | 21,672 | 20,591 | 20,442 | 24,845 | 22,677 | 20,441 | 18,887 | 16,868 | 15,536 | 13,398 | 18,534 | 17,414 | 16,287 | 17,180 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Financial leverage1 | 3.49 | 3.10 | 2.71 | 2.74 | 2.87 | 2.79 | 2.86 | 2.98 | 2.81 | 3.02 | 3.18 | 3.44 | 2.60 | 2.66 | 2.82 | 3.02 | 3.36 | 3.22 | 3.57 | 2.80 | 2.91 | 2.40 | 2.23 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 2.20 | 2.25 | 2.21 | 2.18 | 2.15 | 2.16 | 2.19 | 2.20 | 2.33 | 2.24 | 2.26 | 2.47 | 2.26 | 2.25 | 2.26 | 2.56 | 1.90 | 1.93 | 1.91 | 1.94 | 1.98 | 1.92 | 1.97 | |||||||
AbbVie Inc. | 9.80 | 10.17 | — | — | — | — | — | — | — | — | 19.52 | 13.89 | 10.29 | 11.15 | 13.14 | 14.26 | 10.30 | 11.92 | 11.57 | 13.45 | 11.28 | 9.78 | 19.39 | |||||||
Amgen Inc. | 5.90 | 6.10 | 6.50 | 6.17 | 5.45 | 5.50 | 5.91 | 5.31 | 4.69 | 4.54 | 4.56 | 3.17 | 2.49 | 2.51 | 2.54 | 2.60 | 2.54 | 2.50 | 2.62 | 2.55 | 2.57 | 2.59 | 2.60 | |||||||
Bristol-Myers Squibb Co. | 2.50 | 2.61 | 2.59 | 2.52 | 3.25 | 3.44 | 2.29 | 2.49 | 2.47 | 2.65 | 2.59 | 2.86 | 2.30 | 2.27 | 2.28 | 2.08 | 2.16 | 2.20 | 2.22 | 2.23 | 2.11 | 2.11 | 2.16 | |||||||
Eli Lilly & Co. | 9.10 | 10.25 | 13.35 | 15.07 | 11.20 | 13.91 | 15.32 | 4.47 | 3.41 | 3.67 | 3.05 | 3.88 | 2.89 | 2.90 | 2.68 | 2.77 | 2.41 | 2.49 | 2.31 | 2.44 | 2.39 | 2.46 | 2.39 | |||||||
Illumina Inc. | 1.58 | 1.59 | 1.57 | 1.59 | 1.60 | 1.61 | 1.85 | 1.85 | 1.93 | 1.80 | 1.84 | 1.91 | 1.77 | 1.79 | 1.80 | 1.95 | 1.89 | 1.94 | 1.91 | 1.99 | 1.93 | 2.06 | 2.16 | |||||||
Johnson & Johnson | 2.65 | 2.51 | 2.53 | 2.65 | 2.67 | 2.55 | 2.54 | 2.56 | 2.41 | 2.47 | 2.48 | 2.61 | 2.10 | 2.12 | 2.06 | 2.01 | 1.93 | 1.93 | 1.88 | 1.88 | 1.86 | 1.86 | 1.89 | |||||||
Merck & Co. Inc. | 3.08 | 3.28 | 3.24 | 3.26 | 3.10 | 3.04 | 2.99 | 3.09 | 2.63 | 2.61 | 2.56 | 2.56 | 2.40 | 2.35 | 2.42 | 2.38 | 2.25 | 2.23 | 2.25 | 2.28 | 2.22 | 2.21 | 2.27 | |||||||
Pfizer Inc. | 2.74 | 2.77 | 2.56 | 2.65 | 2.62 | 2.62 | 2.64 | 2.51 | 2.35 | 2.36 | 2.25 | 2.41 | 2.83 | 2.89 | 2.89 | 2.88 | 2.82 | 2.72 | 2.58 | 2.59 | 2.56 | 2.40 | 2.39 | |||||||
Regeneron Pharmaceuticals Inc. | 1.59 | 1.59 | 1.30 | 1.34 | 1.33 | 1.35 | 1.36 | 1.34 | 1.37 | 1.38 | 1.43 | 1.43 | 1.44 | 1.47 | 1.61 | 1.57 | 1.52 | 1.52 | 1.57 | 1.53 | 1.57 | 1.36 | 1.41 | |||||||
Vertex Pharmaceuticals Inc. | 1.39 | 1.36 | 1.38 | 1.37 | 1.43 | 1.39 | 1.39 | 1.41 | 1.59 | 1.61 | 1.65 | 1.75 | 1.79 | 1.97 | 1.96 | 2.50 | 2.55 | 2.60 | 2.60 | 2.66 | 2.64 | 2.65 | 2.22 | |||||||
Zoetis Inc. | 3.81 | 4.38 | 4.19 | 4.26 | 4.21 | 4.56 | 4.70 | 4.93 | 4.94 | 4.37 | 4.43 | 4.85 | 4.67 | 4.55 | 4.75 | 5.14 | 4.87 | 5.54 | 6.40 | 7.41 | 5.44 | 5.61 | 5.03 |
Based on: 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q3 2020 Calculation
Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= 60,878 ÷ 17,445 = 3.49
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Gilead Sciences Inc.’s financial leverage ratio increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Interest Coverage
Gilead Sciences Inc., interest coverage calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income (loss) attributable to Gilead | 360 | (3,339) | 1,551 | 2,696 | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | 4,683 | 4,600 | 4,492 | 4,333 | |||||||
Add: Net income attributable to noncontrolling interest | (7) | (7) | (13) | (7) | (3) | (5) | (7) | — | 2 | 2 | 1 | 29 | (6) | (4) | (3) | (9) | (5) | — | 1 | 2 | (8) | 5 | (1) | |||||||
Add: Income tax expense | 472 | 373 | 465 | (788) | (333) | 535 | 382 | 1,013 | 565 | 267 | 494 | 5,962 | 959 | 1,046 | 918 | 821 | 951 | 902 | 935 | 752 | 880 | 1,014 | 907 | |||||||
Add: Interest expense | 236 | 240 | 241 | 243 | 250 | 248 | 254 | 257 | 264 | 266 | 290 | 297 | 291 | 269 | 261 | 265 | 242 | 227 | 230 | 230 | 165 | 140 | 153 | |||||||
Earnings before interest and tax (EBIT) | 1,061 | (2,733) | 2,244 | 2,144 | (1,251) | 2,658 | 2,604 | 1,273 | 2,928 | 2,352 | 2,323 | 2,423 | 3,962 | 4,384 | 3,878 | 4,185 | 4,518 | 4,626 | 4,732 | 5,667 | 5,637 | 5,651 | 5,392 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Interest coverage1 | 2.83 | 0.41 | 5.90 | 6.19 | 5.24 | 9.25 | 8.80 | 8.24 | 8.98 | 9.67 | 11.41 | 13.10 | 15.11 | 16.36 | 17.29 | 18.74 | 21.04 | 24.25 | 28.35 | 32.48 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 7.66 | 6.80 | 7.39 | 7.09 | 6.47 | 5.67 | 4.99 | 4.48 | 3.82 | 3.67 | 3.13 | 3.47 | 4.12 | 3.43 | 4.58 | 4.28 | 5.29 | 10.30 | 14.76 | 20.53 | — | — | — | |||||||
Amgen Inc. | 7.62 | 7.62 | 7.85 | 8.09 | 7.97 | 7.63 | 7.61 | 7.86 | 7.98 | 8.35 | 8.41 | 8.36 | 8.44 | 8.46 | 8.25 | 8.27 | 8.23 | 8.30 | 8.35 | 8.29 | — | — | — | |||||||
Illumina Inc. | 19.80 | 21.05 | 23.15 | 22.50 | 18.34 | 16.69 | 15.85 | 16.68 | 19.94 | 20.81 | 20.03 | 29.19 | 28.79 | 29.69 | 30.05 | 17.91 | 18.67 | 15.73 | 14.19 | 14.84 | — | — | — | |||||||
Johnson & Johnson | 96.82 | 81.36 | 81.56 | 55.49 | 34.61 | 29.04 | 20.98 | 18.91 | 17.95 | 18.54 | 18.77 | 19.92 | 24.03 | 25.69 | 27.08 | 28.28 | 28.40 | 29.56 | 33.95 | 35.78 | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 72.22 | 108.12 | 90.22 | 81.43 | 72.82 | 69.19 | 86.34 | 91.55 | 91.46 | 93.35 | 93.76 | 83.75 | 85.15 | 103.77 | 119.78 | 185.82 | 158.42 | 135.89 | 120.37 | 87.03 | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 52.77 | 40.26 | 30.99 | 24.84 | 12.91 | 13.16 | 11.02 | 9.28 | 11.26 | 3.07 | 0.05 | 0.73 | -0.65 | 4.75 | 3.80 | 0.17 | -1.01 | -1.63 | -3.67 | -5.62 | — | — | — | |||||||
Zoetis Inc. | 9.79 | 9.72 | 9.71 | 9.08 | 8.88 | 8.46 | 8.69 | 9.20 | 9.64 | 10.12 | 9.87 | 9.71 | 8.99 | 8.60 | 8.52 | 8.40 | 7.54 | 7.66 | 5.65 | 5.40 | — | — | — |
Based on: 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).
1 Q3 2020 Calculation
Interest coverage
= (EBITQ3 2020
+ EBITQ2 2020
+ EBITQ1 2020
+ EBITQ4 2019)
÷ (Interest expenseQ3 2020
+ Interest expenseQ2 2020
+ Interest expenseQ1 2020
+ Interest expenseQ4 2019)
= (1,061 + -2,733 + 2,244 + 2,144)
÷ (236 + 240 + 241 + 243)
= 2.83
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Gilead Sciences Inc.’s interest coverage ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |